AghdamKAPielenAFrammeCJunkerBVisual and anatomic outcomes after conversion to aflibercept in neovascular age-related macular degeneration: 12-month results.Eur J Ophthalmol201626(5)473–478
2.
FreundKBKorobelnikJFDevenyiRet al.Treat-and extend regimens with anti-VEGF agents in retinal diseases.Retina201535(8)1489–1506
3.
PapadopoulosNMartinJRuanQet al.Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab.Angiogenesis201215(2)171–185
4.
CălugăruDCălugăruMComparison of time to retreatment and visual function between ranibizumab and aflibercept in age-related macular degeneration.Am J Ophthalmol2017174(2)181–182
5.
CălugăruDCălugăruMLong-term of pro re nata regimen of aflibercept treatment in persistent neovascular age-related macular degeneration.Am J Ophthalmol2017173(1)145–146
